COVID-19 drug does not improve chances of survival – WHO

Coronavirus, Remdesivir, United States, World Health Organization, Hydroxychloroquine, Mortality rate, Top Stories,

Remdesivir is an experimental antiviral drug that has been used to treat Trump, is ineffective, the WHO study showed, Dailymail, citing information from the Financial Times

Antiviral remdesivir Is one of only two drugs for the treatment of COVID-19 that have received FDA approval in the United States.

The SOLIDARITY study, initiated by the World Health Organization to find an effective drug for the treatment of COVID-19, involved 11,266 hospitalized patients with COVID-19. Doctors studied therapies with remdesivir, hydroxychloroquine, lopinavir, and interferon and concluded that none of the four drugs “significantly affected” mortality rates or improved the chances of survival from COVID-19 or reduced the need for mechanical ventilation.


Note that in the United States, remdesivir is one of two drugs that have received approval from the Food and Drug Administration (FDA).

Remdesivir was prescribed to 2,750 out of more than 11,000 patients in the SOLIDARITY study between March and early October.

The remdesivir treatment cost $ 2,340.

Earlier it was reported that the drug “Bioven”, which is produced by Biopharma Plasma LLC, can be included in the protocol for treating patients with coronavirus.


Public Reaction